Xencor

Xencor, founded in 1997, is at the forefront of the biotechnology sector, revolutionizing treatments for autoimmune diseases, asthma, and cancer through cutting-edge biotherapeutics. Their slogan, "Proteins by Design", encapsulates their innovative approach towards protein engineering.

Leveraging their proprietary XmAb antibody technology, Xencor enhances natural antibody functions, maintaining over 99.5% identity to their natural counterparts, yet delivering increased potency and safety. This breakthrough technology has led to a robust pipeline with eight product candidates in human clinical trials, showcasing its potential as a frontrunner in producing differentiated drugs.

Operating in the United States, Xencor continues to explore new avenues with biosuperiors to improve existing antibody drugs. Despite its established history, the company actively attracts investments, evidenced by a recent $25.00M post-IPO equity injection on 19 November 2021, highlighting its sustained appeal to investors in the healthcare and wellness sectors.